ArticlePloS one2014
A model-based analysis of culture-dependent phenotypes of mESCs.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Modeling unveils sex differences of signaling networks in mouse embryonic stem cells.Molecular systems biology · 2023Article
- Theoretical and computational tools to model multistable gene regulatory networks.Reports on progress in physics. Physical Society (Great Britain) · 2023Review
- Characterization of a Distinct State in the Continuum of Pluripotency Facilitated by Inhibition of PKCζ in Mouse Embryonic Stem Cells.Stem cell reviews and reports · 2023Article
- Nuclear gene proximity and protein interactions shape transcript covariations in mammalian single cells.Nature communications · 2020Article
- Decoding the mechanisms underlying cell-fate decision-making during stem cell differentiation by random circuit perturbation.Journal of the Royal Society, Interface · 2020Article
- Increased expression of stemness genesInternational journal of reproductive biomedicine · 2018Article
- A stochastic and dynamical view of pluripotency in mouse embryonic stem cells.PLoS computational biology · 2018Article
- Modeling signaling-dependent pluripotency with Boolean logic to predict cell fate transitions.Molecular systems biology · 2018Article
- Network Features and Dynamical Landscape of Naive and Primed Pluripotency.Biophysical journal · 2018Article
- Article
- A conceptual and computational framework for modelling and understanding the non-equilibrium gene regulatory networks of mouse embryonic stem cells.PLoS computational biology · 2017Article
- Article
- An extended model for culture-dependent heterogenous gene expression and proliferation dynamics in mouse embryonic stem cells.NPJ systems biology and applications · 2017Article
- Nanog Dynamics in Mouse Embryonic Stem Cells: Results from Systems Biology Approaches.Stem cells international · 2017Review
- Dissecting mechanisms of mouse embryonic stem cells heterogeneity through a model-based analysis of transcription factor dynamics.Journal of the Royal Society, Interface · 2016Article
- Network plasticity of pluripotency transcription factors in embryonic stem cells.Nature cell biology · 2015Article
- Inference of spatiotemporal effects on cellular state transitions from time-lapse microscopy.BMC systems biology · 2015Article
- Quantitative multivariate analysis of dynamic multicellular morphogenic trajectories.Integrative biology : quantitative biosciences from nano to macro · 2015Article
- Stochastic promoter activation affects Nanog expression variability in mouse embryonic stem cells.Scientific reports · 2014Article
- Construction and validation of a regulatory network for pluripotency and self-renewal of mouse embryonic stem cells.PLoS computational biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Mouse embryonic stem cells (mESCs) can be maintained in a proliferative and undifferentiated state over many passages (self-renewal) while retaining the potential to give rise to every cell type of the organism (pluripotency). Autocrine FGF4/Erk signalling has been identified as a major stimulus for fate decisions and lineage commitment in these cells. Recent findings on serum-free culture conditions with specific inhibitors (known as 2i) demonstrate that the inhibition of this pathway reduces transcription factor heterogeneity and is vital to maintain ground state pluripotency of mESCs. We suggest a novel mathematical model to explicitly integrate FGF4/Erk signalling into an interaction network of key pluripotency factors (namely Oct4, Sox2, Nanog and Rex1). The envisaged model allows to explore whether and how proposed mechanisms and feedback regulations can account for different expression patterns in mESC cultures. We demonstrate that an FGF4/Erk-mediated negative feedback is sufficient to induce molecular heterogeneity with respect to Nanog and Rex1 expression and thus critically regulates the propensity for differentiation and the loss of pluripotency. Furthermore, we compare simulation results on the transcription factor dynamics in different self-renewing states and during differentiation with experimental data on a Rex1GFPd2 reporter cell line using flow cytometry and qRT-PCR measurements. Concluding from our results we argue that interaction between FGF4/Erk signalling and Nanog expression qualifies as a key mechanism to manipulate mESC pluripotency. In particular, we infer that ground state pluripotency under 2i is achieved by shifting stable expression pattern of Nanog from a bistable into a monostable regulation impeding stochastic state transitions. Furthermore, we derive testable predictions on altering the degree of Nanog heterogeneity and on the frequency of state transitions in LIF/serum conditions to challenge our model assumptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.